Skip to main content

Table 2 Clinical & demographic details of MS & control cases

From: Calreticulin and other components of endoplasmic reticulum stress in rat and human inflammatory demyelination

   MS cases Control cases
Lab I.D. Sex/Age (y) Disease MS type     Lab ID Sex/Age (y)
Duration (y) Last relapse Steroids (Y/N) Treatment
MS 11/11 M/33 3 RR 5 mo N Natalizumab C2/11 F/45
MS 16/11 F/33 1 RR 1 yr N Copaxone C4/11 F/28
MS 19/11 F/36 3 RR 3 yr N Copaxone C7/11 M/22
MS 24/11 F/32 12 RR 2 yr N Naltrexone C13/11 M/49
MS 31/11 M/49 3 RR 1 yr N Natalizumab C14/11 F/30
MS 32/11 F/44 22 RR 2.5 yr N Natalizumab C16/11 F/33
MS 33/11 F/39 12 RR 1 yr N Natalizumab C17/11 M/31
MS 35/11 F/24 6 RR 2 yr N Natalizumab C23/11 F/82
MS 36/11 F/33 10 RR 2 yr N Natalizumab C24/11 F/39
MS 38/11 F/46 13 RR 3.5 yr N Natalizumab C2/12 F/24
MS 39/11 M/33 6 RR 3.5 yr N Natalizumab C5/12 F/42
MS 41/11 M/29 3 RR 2 yr N Natalizumab   
MS 44/11 F/58 22 RR/SP NK N Copaxone   
MS 47/11 F/48 5 RR 5 yr N Rebif   
  1. Key: mo months, yr years, NK not known.